Methods |
Randomized controlled trial |
Participants |
Patients with active inflammatory bowel disease (ulcerative colitis N = 30, or Crohn's disease N = 30) |
Interventions |
Oral 5‐ASA, 0.5 g three times daily (n = 15) or oral SASP, 1.0 g three times daily (n = 15) for 8 weeks |
Outcomes |
Remission and clinical improvement |
Notes |
Study also enrolled 30 patients with Crohn's disease |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not described |
Allocation concealment (selection bias) |
Unclear risk |
Not described |
Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not described |
Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
Selective reporting (reporting bias) |
Unclear risk |
Not described |
Other bias |
Unclear risk |
Not described |